Avadel ADRs Tumble 14% Following Lawsuit Trying to Overturn FDA Approval of Similar Drug
By Denny Jacob
American depositary receipts of Avadel Pharmaceuticals tumbled 14% to $13.13 on Friday after a lawsuit was filed in the U.S. District Court for the District of Columbia alleging that the U.S. Food and Drug Administration unlawfully approved the company's new drug application for Lumryz.
Avadel's ADRs, which are up 83% on the year, are on pace for their largest percentage decrease since May 2022 when they fell over 68%.
Ireland-based biopharmaceutical company Jazz Pharmaceuticals said Thursday in a regulatory filing that its lawsuit alleged that the FDA acted outside its authority under the Orphan Drug Act when it approved Lumryz's new drug application and granted it orphan drug exclusivity.
The lawsuit alleged the FDA acted without lawful basis when the agency determined that Lumryz boosted patient care and was purportedly clinically superior to two similar drugs that Jazz Pharmaceutical produces, Xywav and Xyrem.
Jazz Pharmaceuticals said Xywav already had orphan drug exclusivity and described Lumryz as an extended-release reformulation of Xyrem. The drugs treat cataplexy, or excessive daytime sleepiness, in adults with narcolepsy.
Avadel Pharmaceuticals didn't immediately respond to a request for comment from Dow Jones Newswires.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 23, 2023 11:57 ET (15:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits